Curis, Inc. (NASDAQ: CRIS) reported its financial results for the three months ended September 30, 2026, and provided an update on its clinical development of emavusertib (CA-4948). The company reported a net loss of $8.1 million for the third quarter of 2026, or $1.94 per share, compared to a net loss of $7.7 million, or $9.86 per share, for the same period in 2025. For the nine months ended September 30, 2026, the net loss was $40.9 million, or $16.77 per share, compared to a net loss of $26.9 million, or $43.82 per share, for the same period in 2025.
Curis reported no revenue for the quarter or the year ended September 30, 2026, due to the sale of Erivedge royalties in the fourth quarter of 2025. In comparison, revenues were $3.2 million for the quarter and $8.3 million for the year ended September 30, 2025. Research and development expenses decreased to $5.6 million for the third quarter of 2026, down from $6.4 million in the prior year, while general and administrative expenses decreased to $3.2 million for the third quarter of 2026, down from $3.7 million in the prior year.
As of September 30, 2026, the company held $5.0 million in cash and cash equivalents. Curis stated that this cash balance, combined with net proceeds of approximately $7.5 million from a private placement completed in October 2026, should fund operations into the first quarter of 2027. The company also completed a public offering in August 2026.
On the clinical front, Curis is currently enrolling patients in two ongoing studies: the TakeAim CLL study (CA-4948-203) and the TakeAim Lymphoma study in primary central nervous system lymphoma (PCNSL) (CA-4948-101). The TakeAim CLL study is a phase 2 open-label trial of emavusertib combined with zanubrutinib for patients with chronic lymphocytic leukemia who have received zanubrutinib for at least 12 months. To date, 12 patients have been enrolled, with initial data expected in December 2026.
The TakeAim Lymphoma study is a registrational trial of emavusertib combined with ibrutinib for patients with relapsed/refractory PCNSL. In July 2026, the company reported updated data for 46 patients (7 BTK-naïve and 39 BTKi-experienced). The overall response rate was 33% for evaluable BTKi-experienced patients and 100% for BTK-naïve patients. The company stated that it received guidance from the FDA and EMA in 2025 that the ongoing registrational study could support regulatory applications for accelerated approval in R/R PCNSL.
